Hormone replacement therapy in patients with heart defects
The authors studied the course of climacteric syndrome in patients with congenital and acquired heart defect diseases and its correction using hormone replacement therapy (HRT). The examination involved 27 patients aged from 40 to 53 years. The study has shown that in patients with heart defects problems of estrogen-deficient conditions characteristic for climacteric syndrome are topical. The possibility of using natural estrogen analogues for hormone replacement therapy shifts the emphasis of selecting a combined drug to the properties of the gestagen component. For patients with cardiovascular diseases the choice of gestagen is important in principle and not infrequently it is a limiting factor.